



Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

Romain Sechaud¹ · Helen Gu² · Gholamreza Rahmanzadeh¹ · Amanda Taylor² · Ovidiu Chiparus² · Gopal Krishna Sharma³ · Astrid Breitschaft⁴ · Hans D. Menssen¹

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024

Correction to: Cancer Chemotherapy and Pharmacology <https://doi.org/10.1007/s00280-023-04635-3>

The article “Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants”, written by Romain Sechaud Helen Gu Gholamreza Rahmanzadeh Amanda Taylor Ovidiu Chiparus ·Gopal Krishna Sharma Astrid Breitschaft and Hans D. Menssen was originally published electronically on the publisher's internet portal (currently SpringerLink) on 25th January 2024 with

open access. With the author(s)' decision to step back from Open Choice, the copyright of the article changed on 12th February 2024 to © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024 and the article is forthwith distributed under the terms of copyright.

The original article has been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00280-023-04635-3>.

✉ Romain Sechaud
romain.sechaud@novartis.com

Helen Gu
helen.gu@novartis.com

Gholamreza Rahmanzadeh
gholamreza.rahmanzadeh@novartis.com

Amanda Taylor
amandaj.taylor@novartis.com

Ovidiu Chiparus
ovidiu.chiparus@novartis.com

Gopal Krishna Sharma
gopal_krishna.sharma@novartis.com

Astrid Breitschaft
Astrid.Breitschaft@parexel.com

Hans D. Menssen
hans.menssen@novartis.com

- ¹ Novartis Pharma AG, 4002 Basel, Switzerland
- ² Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- ³ Novartis Healthcare Pvt. Ltd., Hyderabad, Telangana 50081, India
- ⁴ Parexel International GmbH, 14059 Berlin, Germany